BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/15/2021 4:26:47 AM | Browse: 480 | Download: 1193
 |
Received |
|
2020-11-18 08:03 |
|
Peer-Review Started |
|
2020-11-16 08:33 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-12-30 20:32 |
|
Revised |
|
2021-01-13 08:08 |
|
Second Decision |
|
2021-02-22 13:20 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-02-23 06:22 |
|
Articles in Press |
|
2021-02-23 06:22 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-03-10 06:17 |
|
Typeset the Manuscript |
|
2021-03-19 01:35 |
|
Publish the Manuscript Online |
|
2021-04-15 04:26 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Partial respond to Chinese patent medicine kangliu pill for adult glioblastoma: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ge Sun, Wei Zhuang, Qing-Tang Lin, Lei-Ming Wang, Yu-Hang Zhen, Sheng-Yan Xi and Xiao-Lan Lin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The Foundation for Beijing Science and Technology Development of TCM |
JJ2016-10 |
| The National Traditional Chinese Medicine Innovative Talents Training Project from Beijing Municipal Science and Technology Commission |
Z171100001717006 |
|
| Corresponding Author |
Xiao-Lan Lin, N/A, Chief Pharmacist, Reader (Associate Professor), Department of Pharmacy, Xuanwu Hospital of Capital Medical University, No. 45, Changchun Street, Beijing 100053, China. xllin83@163.com |
| Key Words |
Glioblastoma; Kangliu Pill; Traditional Chinese medicine; Therapeutic effect; Adjunct therapy; Chinese patent medicine; Case report |
| Core Tip |
Glioblastoma is the most common type of malignant primary brain cancer. The standard treatment for newly diagnosed glioblastoma includes surgery followed by concurrent chemoradiotherapy and further adjuvant temozolomide. However, patients usually have a poor prognosis and high recurrence rate, and may develop drug resistance and serious adverse reactions to chemotherapy. Some recent studies suggested that traditional Chinese medicine may have a good therapeutic effect in patients with glioblastoma, and it is generally used as an adjunct therapy for various stages of tumors in clinical practice. In this case, we report a patient with glioblastoma who abandoned chemoradiotherapy because of intolerance, and subsequently received the Chinese patent medicine Kangliu pill without any other treatment. Three months after the start of treatment, the patient had a partial response, which persisted for more than 3 years. This surprising discovery indicates that the Chinese patent medicine Kangliu pill may provide a new option for the treatment of glioblastoma. |
| Publish Date |
2021-04-15 04:26 |
| Citation |
Sun G, Zhuang W, Lin QT, Wang LM, Zhen YH, Xi SY, Lin XL. Partial respond to chinese patent medicine kangliu pill for adult glioblastoma: A case report and review of literature. World J Clin Cases 2021; 9(12): 2845-2853 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i12/2845.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i12.2845 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
